Artwork

Contenu fourni par Zühlke. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Zühlke ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Player FM - Application Podcast
Mettez-vous hors ligne avec l'application Player FM !

Data and Alzheimer’s Testing with Rhoda Au

27:28
 
Partager
 

Manage episode 412953051 series 3456968
Contenu fourni par Zühlke. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Zühlke ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

According to Alzheimer's Disease International, the number of people around the world with the condition will reach 78 million in 2030, and 139 million in 2050. As of 2024, there is no known cure for Alzheimer's, dementia, or similar degenerative brain conditions. So, how are those testing for these diseases using data and technology to help improve health outcomes?

Today’s guest is Rhoda Au, Professor of Anatomy & Neurobiology, Neurology, and Epidemiology at Boston University, and Director of Neuropsychology at the Framingham Heart Study. She’s also the Director of Global Cohort Development at the Davos Alzheimer's Collaborative.

We discuss Rhoda’s experience of paper-and-pen Alzheimer's testing in the early 90s, her switch to voice capture in 2005, and her thoughts about how medical data should be shared.

00:00 - Intro

02:02 - The pen-and-paper days of Altizmer’s testing

12:34 - The ethics of voice capture

20:20 - Why we need to open up health data to the community

26:07 - Dan's final thoughts

LINKS:

Rhoda Au: https://www.linkedin.com/in/rhoda-au-1687277/

Boston University School of Medicine & Public Health: https://www.bu.edu/sph/

Framingham Heart Study: https://www.framinghamheartstudy.org/

Alzheimer's Disease International: https://www.alzint.org/

Alzheimer's Disease Data Initiative: https://www.alzheimersdata.org/

Dan Klein: https://uk.linkedin.com/in/dplklein

Zühlke: https://www.zuehlke.com/en

Welcome to Data Today, a podcast from Zühlke.

We're living in a world of opportunities. But to fully realise them, we have to reshape the way we innovate.

We need to stop siloing data, ring-fencing knowledge and looking at traditional value chains. And that's what this podcast is about. Every two weeks, we’re taking a look at data outside the box to see how amazing individuals from disparate fields and industries are transforming the way they work with data, the challenges they are overcoming, and what we can all learn from them.

Zühlke is a global innovation service provider. We envisage ideas and create new business models for our clients by developing services and products based on new technologies – from the initial vision through development to deployment, production and operation.

  continue reading

17 episodes

Artwork
iconPartager
 
Manage episode 412953051 series 3456968
Contenu fourni par Zühlke. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Zühlke ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

According to Alzheimer's Disease International, the number of people around the world with the condition will reach 78 million in 2030, and 139 million in 2050. As of 2024, there is no known cure for Alzheimer's, dementia, or similar degenerative brain conditions. So, how are those testing for these diseases using data and technology to help improve health outcomes?

Today’s guest is Rhoda Au, Professor of Anatomy & Neurobiology, Neurology, and Epidemiology at Boston University, and Director of Neuropsychology at the Framingham Heart Study. She’s also the Director of Global Cohort Development at the Davos Alzheimer's Collaborative.

We discuss Rhoda’s experience of paper-and-pen Alzheimer's testing in the early 90s, her switch to voice capture in 2005, and her thoughts about how medical data should be shared.

00:00 - Intro

02:02 - The pen-and-paper days of Altizmer’s testing

12:34 - The ethics of voice capture

20:20 - Why we need to open up health data to the community

26:07 - Dan's final thoughts

LINKS:

Rhoda Au: https://www.linkedin.com/in/rhoda-au-1687277/

Boston University School of Medicine & Public Health: https://www.bu.edu/sph/

Framingham Heart Study: https://www.framinghamheartstudy.org/

Alzheimer's Disease International: https://www.alzint.org/

Alzheimer's Disease Data Initiative: https://www.alzheimersdata.org/

Dan Klein: https://uk.linkedin.com/in/dplklein

Zühlke: https://www.zuehlke.com/en

Welcome to Data Today, a podcast from Zühlke.

We're living in a world of opportunities. But to fully realise them, we have to reshape the way we innovate.

We need to stop siloing data, ring-fencing knowledge and looking at traditional value chains. And that's what this podcast is about. Every two weeks, we’re taking a look at data outside the box to see how amazing individuals from disparate fields and industries are transforming the way they work with data, the challenges they are overcoming, and what we can all learn from them.

Zühlke is a global innovation service provider. We envisage ideas and create new business models for our clients by developing services and products based on new technologies – from the initial vision through development to deployment, production and operation.

  continue reading

17 episodes

Tous les épisodes

×
 
Loading …

Bienvenue sur Lecteur FM!

Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.

 

Guide de référence rapide